All In Biotech

Drug Trial Radar · NCT05623982

A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

An Open, Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Tetra-specific Antibody GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 26, 2022

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Sponsor type
Industry
Collaborators
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted
Nov 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To explore the safety and preliminary efficacy of GNC-038 in patients with relapsed or refractory NHL, and to determine the MTD and RP2D of GNC-038, or the MAD and DLT

Conditions

  • Non-hodgkin's Lymphoma

Interventions

  • GNC-038Drug

    Administration by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: Up to 14 days after the first dose
  2. Maximum tolerated dose (MTD) or Maximum dose (MAD)Time frame: Up to 14 days after the first dose
  3. Adverse Events during Treatment (TEAE)Time frame: Up to approximately 24 months
  4. Recommended dose for Phase II clinical studies (RP2D)Time frame: Up to 14 days after the first dose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Harbin First Hospital

    Haerbin, Heilongjing, China · Recruiting

  • Qingdao Central Hospital

    Qingdao, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.